Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Cumulative dose

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44346   clinical trials with a EudraCT protocol, of which   7374   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    780 result(s) found for: Cumulative dose. Displaying page 8 of 39.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    EudraCT Number: 2016-003154-32 Sponsor Protocol Number: N/A Start Date*: 2017-09-18
    Sponsor Name:University of Leeds
    Full Title: SPAARK: Study of Peri-Articular Anaesthetic for Replacement of the Knee. The clinical and cost effectiveness of peri-articular liposomal bupivacaine compared with bupivacaine hydrochloride alone fo...
    Medical condition: Local anaesthetic for patients undergoing knee replacement surgery for arthritis
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2020-001442-19 Sponsor Protocol Number: IIBSP-COV-2020-23 Start Date*: 2020-04-02
    Sponsor Name:INSTITUT DE RECERCA H. SANTA CREU I SANT PAU
    Full Title: Pilot, randomized, multicenter, open-label clinical trial of combined use of hydroxychloroquine, azithromycin, and tocilizumab for the treatment of SARS-CoV-2 infection (COVID-19)
    Medical condition: COVID19
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-006201-29 Sponsor Protocol Number: SC102021 Start Date*: 2022-04-28
    Sponsor Name:University Hospitals Leuven
    Full Title: Erector spinae plane (ESP) block versus intercostal nerve blocks (ICNB) in uniportal videoscopic assisted thoracic surgery (VATS): A multicenter double-blind, prospective, randomized controlled trial.
    Medical condition: Postoperative pain treatment after uniportal videoscopic assisted thoracic surgery (VATS).
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004865 10036236 Postoperative pain relief LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002625-20 Sponsor Protocol Number: SC052021 Start Date*: 2021-08-31
    Sponsor Name:University Hospitals Leuven
    Full Title: Intrathecal morphine administration for minimally invasive pancreatic surgery: A double blind, prospective randomized placebo-controlled trial.
    Medical condition: postoperative pain treatment after minimally invasive pancreatic surgery
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2017-005162-22 Sponsor Protocol Number: PSS2017/PCE-aGVHD-RUBIO/VS Start Date*: 2018-05-22
    Sponsor Name:CHRU de Nancy
    Full Title: A multi-center randomized phase II study comparing corticosteroids alone versus corticosteroids and extracorporal photopheresis (ECP) as first-line treatment of standard risk Grade II acute graft-v...
    Medical condition: Standard II acute graft-versus-host disease following allogeneic stem cell transplantation
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2020-002295-13 Sponsor Protocol Number: APHP200552 Start Date*: 2020-10-15
    Sponsor Name:Assistance Publique - Hôpitaux Paris
    Full Title: Evaluation of the efficacy, safety and tolerability of alisporivir for the treatment of hospitalised patients with infections due to SARS-CoV-2 (COVID-19). A randomised, open-label, proof of conc...
    Medical condition: The study population will consist of adults (18-80 years old) hospitalised for ≤48 hours prior to randomisation with a diagnosis of COVID-19 based on symptoms onset and SARS-CoV-2 RT-PCR test posit...
    Disease: Version SOC Term Classification Code Term Level
    23.0 10021881 - Infections and infestations 10051905 Coronavirus infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2017-004616-19 Sponsor Protocol Number: ABT-gpCPT001 Start Date*: 2018-09-12
    Sponsor Name:ASIT biotech S.A.
    Full Title: A dose-ranging clinical study to determine the range of grass pollen allergen (gpCPT+) concentrations to be used in a conjunctival provocation test to grade moderate to severe grass pollen allergic...
    Medical condition: This clinical trial aims to evaluate a conjunctival provocation test (CPT) with the IMP gpCPT+ for the assessment and grading of grass pollen allergic rhinoconjunctivitis. Thus, a diagnostic solu...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004853 10001728 Allergic rhinoconjunctivitis LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000391-34 Sponsor Protocol Number: 1200.43 Start Date*: 2011-10-25
    Sponsor Name:Boehringer Ingelheim
    Full Title: LUX-Head & Neck 1 A randomised, open-label, phase III study to evaluate the efficacy and safety of oral afatinib (BIBW 2992) versus intravenous methotrexate in patients with recurrent and/or metas...
    Medical condition: Recurrent and/or metastatic head and neck squamous cell carcinoma in patients who have progessed after platinum based therapy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10060121 Squamous cell carcinoma of head and neck PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) DK (Completed) FR (Completed) DE (Completed) GR (Completed) ES (Completed) AT (Completed) CZ (Completed) SE (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2004-000211-26 Sponsor Protocol Number: D5890L00007 Start Date*: 2004-08-04
    Sponsor Name:AstraZeneca AB
    Full Title: A comperative, placebo-controlled, doubleblind, double dummy, cross over, single center phase IIIb study between formoterol alone and the fixed combination of formoterol and budesonide on airway re...
    Medical condition: Patient with stable and mild allergic asthma.
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: SE (Completed)
    Trial results: View results
    EudraCT Number: 2012-000398-21 Sponsor Protocol Number: ESTEVE-SIGM-202 Start Date*: 2012-06-21
    Sponsor Name:Laboratorios del Dr. Esteve, S.A.
    Full Title: A proof-of-concept phase 2, randomized, placebo-controlled, double blind, multicentre clinical trial in 2 parallel groups to evaluate the efficacy and safety of E-52862 for reducing the incidence a...
    Medical condition: OXL-induced chronic neuropathy.
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029205 - Nervous system disorders 10029350 Neurotoxicity PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2021-002087-47 Sponsor Protocol Number: ARC001 Start Date*: 2021-12-07
    Sponsor Name:Aimmune Therapeutics, Inc.
    Full Title: Oral Desensitization to Peanut in Peanut-Allergic Children and Adults using Characterized Peanut Allergen (CPNA) Oral Immunotherapy (OIT)
    Medical condition: Peanut Allergy
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2016-003833-91 Sponsor Protocol Number: KF7013-02 Start Date*: 2018-10-04
    Sponsor Name:Grünenthal GmbH
    Full Title: Randomized, double-blind, placebo-controlled trial investigating the efficacy and safety of intravenous neridronic acid in subjects with complex regional pain syndrome (CRPS)
    Medical condition: Complex Regional Pain Syndrome (CRPS).
    Disease: Version SOC Term Classification Code Term Level
    20.1 100000004852 10064334 Complex regional pain syndrome Type I LLT
    20.1 100000004852 10064335 Complex regional pain syndrome Type II LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2020-000996-19 Sponsor Protocol Number: MAA-304 Start Date*: Information not available in EudraCT
    Sponsor Name:Catalyst Biosciences, Inc.
    Full Title: Phase 3 Study to Evaluate the Efficacy and Safety of Subcutaneous Marzeptacog Alfa (Activated) For On-Demand Treatment and Control of Bleeding Episodes in Subjects with Haemophilia A or Haemophilia...
    Medical condition: Marzeptacog alfa (activated) (MarzAA), a novel activated recombinant Factor VII (rFVIIa) variant, is being developed by Catalyst Biosciences to address the unmet need in haemophilia and other bleed...
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10066439 Hemophilia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) HU (Prematurely Ended) PL (Prematurely Ended) DK (Prematurely Ended) BG (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2017-000764-15 Sponsor Protocol Number: ETAL-4 Start Date*: 2017-12-11
    Sponsor Name:Goethe Universität Frankfurt / Universitätsklinikum Frankfurt
    Full Title: European Intergroup Trial on panobinostat maintenance after HSCT for high-risk AML and MDS - A randomized, multicenter phase III study to assess the efficacy of panobinostat maintenance therapy vs....
    Medical condition: High risk acute myeloid leukemia or myelodysplastic syndrome
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) NL (Prematurely Ended) NO (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-005697-71 Sponsor Protocol Number: 060402 Start Date*: 2006-01-26
    Sponsor Name:Baxalta Innovations GmbH
    Full Title: Antihemophilic Factor (Recombinant) Plasma/Albumin-Free Method (rAHF PFM): A Phase 3/4, Prospective, Controlled, Randomized, Multi-Center Study to Compare the Efficacy and Safety of Continuous Infu...
    Medical condition: Subjects with Severe or Moderately Severe Hemophilia A (baseline factor VIII (FVIII) level <= 2% of normal) hemophilia A undergoing major orthopedic surgery
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004850 10060612 Hemophilia A LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed) SE (Completed) BE (Completed) PT (Completed) ES (Completed) HU (Completed) NL (Completed) GB (Completed) IT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2021-001964-11 Sponsor Protocol Number: 2019/0411/HP Start Date*: 2021-12-17
    Sponsor Name:CHU de Rouen
    Full Title: Randomized double blind controlled trial comparing the safety and efficacy of apremilast versus placebo in severe forms of recurrent aphthous stomatitis
    Medical condition: Patients with severe forms of Recurrent Aphthous Stomatitis (RAS)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004856 10045372 Ulcers aphthous oral LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2015-003551-22 Sponsor Protocol Number: 55029 Start Date*: 2016-12-28
    Sponsor Name:Erasmus MC - Sophia Children's Hospital
    Full Title: STATIC IV: Efficacy of a loading dose of intravenous salbutamol in patients admitted to a PICU for severe acute asthma
    Medical condition: Severe acute (viral) wheeze and severe acute asthma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10047921 Wheeze LLT
    19.0 10038738 - Respiratory, thoracic and mediastinal disorders 10041961 Status asthmaticus PT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2016-002129-12 Sponsor Protocol Number: P150955 Start Date*: 2016-10-12
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
    Full Title: A randomized phase IIb study of cyclophosphamide (Cy) versus anti-thymocyte globulin (ATG) for the prophylaxis of graft-versus-host disease (GVHD) after reduced-intensity conditioning allogeneic pe...
    Medical condition: Women and men with a hematologic malignancy for which a reduced-intensity conditioning allo-SCT is indicated
    Disease: Version SOC Term Classification Code Term Level
    19.0 10042613 - Surgical and medical procedures 10053239 Prophylaxis against graft versus host disease PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-004764-30 Sponsor Protocol Number: BRD11/6-N Start Date*: Information not available in EudraCT
    Sponsor Name:CHU Nantes
    Full Title: Phase 2 study of a reduced-toxicity myeloablative conditionning regimen using fludarabine and full doses of IV busulfan in pediatric patients not eligible for standard myeloablative conditioning r...
    Medical condition: Hematological malignancy
    Disease: Version SOC Term Classification Code Term Level
    14.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066481 Hematological malignancy LLT
    Population Age: Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: FR (Completed)
    Trial results: (No results available)
    EudraCT Number: 2018-003753-13 Sponsor Protocol Number: P160909 Start Date*: 2019-03-19
    Sponsor Name:ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS
    Full Title: Multicentre, randomized, prospective trial comparing the efficacy and safety of Infliximab to tocilizumab in refractory or relapsing Takayasu arteritis
    Medical condition: Patients with refractory or relapsing Takayasu Arteritis desease
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Trial now transitioned)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 4  5  6  7  8  9  10  11  12  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Wed Jun 25 01:32:03 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA